FDA nod for Biohaven's Nurtec ODT for migraine prevention

28 May 2021

The US Food and Drug Administration has approved Nurtec ODT (rimegepant 75mg) for the preventive treatment of migraine, thus the drug becomes the first oral CGRP antagonist option to both prevent and treat migraines. Nurtec ODT is indicated for adult patients with episodic migraine, eg, those who experience less than 15 headache days per month.

The news sent shares of the drug’s developer, Biohaven Pharmaceutical (NYSE: BHVN) up 3% to $85.00 in after-hours trading on Thursday.

The FDA first approved Biohaven’s Nurtec ODT for the acute treatment of migraine in adults. In February last year. Total revenues from Nurtec ODT were $43.8 million in the first quarter 2021, up around 24.8% sequentially. Revenues were in line with the Zacks Consensus Estimate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK